Arsenic trioxide targets MTHFD1 and SUMO-dependent nuclear de novo thymidylate biosynthesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 12, 2017, Pages E2319-E2326

  Kamynina, Elena A ^a   Lachenauer, Erica R ^a   DiRisio, Aislyn C ^a   Liebenthal, Rebecca P ^a   Field, Martha S ^a   Stover, Patrick J ^a  

^a Cornell University ^*  (United States)

Author keywords

Arsenic trioxide; Genome instability; MTHFD1; One carbon metabolism; SUMO 1

Indexed keywords

ARSENIC TRIOXIDE; CELL NUCLEUS DNA; DIHYDROFOLATE REDUCTASE; DNA; GLYCINE HYDROXYMETHYLTRANSFERASE; METHYLENETETRAHYDROFOLIC ACID; MULTIENZYME COMPLEX; SUMO 1 PROTEIN; THYMIDINE PHOSPHATE; THYMIDYLATE SYNTHASE; URACIL; FORMATE TETRAHYDROFOLATE LIGASE; FORMYL-METHENYL-METHYLENETETRAHYDROFOLATE SYNTHETASE; HYDROLASE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; ORGANOARSENIC DERIVATIVE; OXIDE; SUMO PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA REPLICATION; EMBRYO; FEMALE; GENOMIC INSTABILITY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUMOYLATION; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL LINE; CELL NUCLEUS; DRUG EFFECT; ENZYMOLOGY; FIBROBLAST; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM;

AMINOHYDROLASES; ANIMALS; ARSENICALS; CELL LINE; CELL NUCLEUS; FIBROBLASTS; FORMATE-TETRAHYDROFOLATE LIGASE; GENOMIC INSTABILITY; GLYCINE HYDROXYMETHYLTRANSFERASE; HUMANS; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP); MICE; MICE, KNOCKOUT; MULTIENZYME COMPLEXES; OXIDES; PROTEOLYSIS; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; THYMIDINE MONOPHOSPHATE; THYMIDYLATE SYNTHASE; URACIL;

EID: 85016132126     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1619745114     Document Type: Article

References (59)

1. Beaudin AE, et al. (2011) Shmt1 and de novo thymidylate biosynthesis underlie folateresponsive neural tube defects in mice. Am J Clin Nutr 93(4):789-798.
2. MacFarlane AJ, et al. (2011) Nuclear localization of de novo thymidylate biosynthesis pathway is required to prevent uracil accumulation in DNA. J Biol Chem286(51):44015-44022.
3. Mathews CK (2006) DNA precursor metabolism and genomic stability. FASEB J 20(9): 1300-1314.
4. Herbig K, et al. (2002) Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J Biol Chem 277(41):38381-38389.
5. MacFarlane AJ, et al. (2008) Cytoplasmic serine hydroxymethyltransferase regulates the metabolic partitioning of methylenetetrahydrofolate but is not essential in mice. J Biol Chem 283(38):25846-25853.
6. MacFarlane AJ, Perry CA, McEntee MF, Lin DM, Stover PJ (2011) Mthfd1 is a modifier of chemically induced intestinal carcinogenesis. Carcinogenesis 32(3):427-433.
7. Hendriks IA, D'Souza RC, Chang JG, Mann M, Vertegaal AC (2015) System-wide identification of wild-type SUMO-2 conjugation sites. Nat Commun 6:7289.
8. Hendriks IA, et al. (2014) Uncovering global SUMOylation signaling networks in a sitespecific manner. Nat Struct Mol Biol 21(10):927-936.
9. Golebiowski F, et al. (2009) System-wide changes to SUMO modifications in response to heat shock. Sci Signal 2(72):ra24.
10. Tammsalu T, et al. (2014) Proteome-wide identification of SUMO2 modification sites. Sci Signal 7(323):rs2.
11. Anderson DD, Eom JY, Stover PJ (2012) Competition between sumoylation and ubiquitination of serine hydroxymethyltransferase 1 determines its nuclear localization and its accumulation in the nucleus. J Biol Chem 287(7):4790-4799.
12. Anderson DD, Woeller CF, Chiang EP, Shane B, Stover PJ (2012) Serine hydroxymethyltransferase anchors de novo thymidylate synthesis pathway to nuclear lamina for DNA synthesis. J Biol Chem 287(10):7051-7062.
13. Anderson DD, Woeller CF, Stover PJ (2007) Small ubiquitin-like modifier-1 (SUMO-1) modification of thymidylate synthase and dihydrofolate reductase. Clin Chem Lab Med 45(12):1760-1763.
14. Field MS, et al. (2014) Nuclear enrichment of folate cofactors and methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) protect de novo thymidylate biosynthesis during folate deficiency. J Biol Chem 289(43):29642-29650.
15. Field MS, Kamynina E, Stover PJ (2016) MTHFD1 regulates nuclear de novo thymidylate biosynthesis and genome stability. Biochimie 126:27-30.
16. Woeller CF, Anderson DD, Szebenyi DM, Stover PJ (2007) Evidence for small ubiquitinlike modifier-dependent nuclear import of the thymidylate biosynthesis pathway. J Biol Chem 282(24):17623-17631.
17. Tibbetts AS, Appling DR (2010) Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr 30:57-81.
18. Field MS, Kamynina E, Watkins D, Rosenblatt DS, Stover PJ (2015) Human mutations in methylenetetrahydrofolate dehydrogenase 1 impair nuclear de novo thymidylate biosynthesis. Proc Natl Acad Sci USA 112(2):400-405.
19. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3(5):330-338.
20. Stover PJ (2011) Polymorphisms in 1-carbon metabolism, epigenetics and folaterelated pathologies. J Nutrigenet Nutrigenomics 4(5):293-305.
21. Watkins D, Rosenblatt DS (2012) Update and new concepts in vitamin responsive disorders of folate transport and metabolism. J Inherit Metab Dis 35(4):665-670.
22. Fox JT, Stover PJ (2008) Folate-mediated one-carbon metabolism. Vitam Horm 79: 1-44.
23. Stover PJ (2004) Physiology of folate and vitamin B12 in health and disease. Nutr Rev 62(6 Pt 2):S3-12; discussion S13.
24. Blount BC, et al. (1997) Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci USA 94(7):3290-3295.
25. Aherne GW, Brown S (1999) The role of uracil misincorporation in thymineless death. Antifolate Drugs in Cancer Therapy, ed Jackman AL (Humana Press, New York), pp 409-421.
26. Porecha RH, Stivers JT (2008) Uracil DNA glycosylase uses DNA hopping and shortrange sliding to trap extrahelical uracils. Proc Natl Acad Sci USA 105(31):10791-10796.
27. Rothkamm K, et al. (2015) DNA damage foci: Meaning and significance. Environ Mol Mutagen 56(6):491-504.
28. MacFarlane AJ, et al. (2009) Mthfd1 is an essential gene in mice and alters biomarkers of impaired one-carbon metabolism. J Biol Chem 284(3):1533-1539.
29. Beaudin AE, Perry CA, Stabler SP, Allen RH, Stover PJ (2012) Maternal Mthfd1 disruption impairs fetal growth but does not cause neural tube defects in mice. Am J Clin Nutr 95(4):882-891.
30. Field MS, et al. (2013) Reduced MTHFD1 activity in male mice perturbs folate- and choline- dependent one-carbon metabolism as well as transsulfuration. J Nutr 143(1):41-45.
31. Watkins D, et al. (2011) Novel inborn error of folate metabolism: Identification by exome capture and sequencing of mutations in the MTHFD1 gene in a single proband. J Med Genet 2011;48(9):590-592.
32. Field MS, Kamynina E, Watkins D, Rosenblatt DS, Stover PJ (2015) New insights into the metabolic and nutritional determinants of severe combined immunodeficiency. Rare Dis 3(1):e1112479.
33. Parle-McDermott A, et al. (2006) Confirmation of the R653Q polymorphism of the trifunctional C1-synthase enzyme as a maternal risk for neural tube defects in the Irish population. Eur J Hum Genet 14(6):768-772.
34. Christensen KE, et al. (2009) The MTHFD1 p.Arg653Gln variant alters enzyme function and increases risk for congenital heart defects. Hum Mutat 30(2):212-220.
35. Beaudin AE, Stover PJ (2009) Insights into metabolic mechanisms underlying folateresponsive neural tube defects: A minireview. Birth Defects Res A Clin Mol Teratol 85(4):274-284.
36. Atta CA, et al. (2016) Global birth prevalence of spina bifida by folic acid fortification status: A systematic review and meta-analysis. Am J Public Health 106(1):e24-e34.
37. Mazumdar M, et al. (2015) Arsenic is associated with reduced effect of folic acid in myelomeningocele prevention: a case control study in Bangladesh. Environ Health 2015;14:34.
38. ATSDR AfTSaDR (2007) Toxicological profile for Arsenic. (US Department of Health and Human Services, Public Health Service, Atlanta). Available at www.atsdr.cdc.gov/ toxprofiles/tp.asp?id=22&tid=3. Accessed April 12, 2016.
39. IARC (2004) Arsenic in drinking water. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (International Agency for Research on Cancer (IARC), Lyon, France) Vol 84, pp 39-267.
40. Wlodarczyk BJ, Bennett GD, Calvin JA, Finnell RH (1996) Arsenic-induced neural tube defects in mice: Alterations in cell cycle gene expression. Reprod Toxicol 10(6):447-454.
41. IARC (2012) Arsenic and arsenic compounds. Arsenic, Metals, Fibres, and Dusts, IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, (IARC, Lyon, France), Vol 100C, pp 41-93. Available at http://monographs.iarc.fr/ENG/Monographs/vol100C/ mono100C.pdf. Accessed April 12, 2016.
42. Lai YL, et al. (2003) Combined effect of topical arsenic trioxide and radiation therapy on skin-infiltrating lesions of breast cancer-a pilot study. Anticancer Drugs 14(10):825-828.
43. Podolsky L, et al. (2011) 5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: A clinical experience. Acta Oncol 50(4): 602-605.
44. Platzbecker U, et al. (2017) Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 Trial. J Clin Oncol 35(6):605-612.
45. de Thé H, Chen Z (2010) Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat Rev Cancer 10(11):775-783.
46. Becker J, et al. (2013) Detecting endogenous SUMO targets in mammalian cells and tissues. Nat Struct Mol Biol 20(4):525-531.
47. Lallemand-Breitenbach V, et al. (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10(5):547-555.
48. Lam SK, et al. (2014) Downregulation of thymidylate synthase with arsenic trioxide in lung adenocarcinoma. Int J Oncol 44(6):2093-2102.
49. Lamm N, et al. (2015) Folate levels modulate oncogene-induced replication stress and tumorigenicity. EMBO Mol Med 7(9):1138-1152.
50. Hagen L, et al. (2008) Cell cycle-specific UNG2 phosphorylations regulate protein turnover, activity and association with RPA. EMBO J 27(1):51-61.
51. World Health Organization (2008) Guidelines for drinking-water quality: Incorporating first and second addenda (WHO Press, Geneva), 3rd Ed.
52. Huang Y, et al. (2008) Induction of cytoplasmic accumulation of p53: A mechanism for low levels of arsenic exposure to predispose cells for malignant transformation. Cancer Res 68(22):9131-9136.
53. Li B, et al. (2016) Arsenic Attenuates GLI Signaling, Increasing or Decreasing its Transcriptional Program in a Context-Dependent Manner. Mol Pharmacol 89(2):226-232.
54. Ding W, Tong Y, Zhang X, Pan M, Chen S (2016) Study of arsenic sulfide in solid tumor cells reveals regulation of nuclear factors of activated T-cells by PML and p53. Sci Rep 6:19793.
55. Ardalan B, et al. (2010) A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res 16(11):3019-3027.
56. Ally MS, et al. (2016) Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatol 152(4):452-456.
57. Sekeres MA, et al. (2011) A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 117(6):1253-1261.
58. Visentin M, Zhao R, Goldman ID (2012) The antifolates. Hematol Oncol Clin North Am 26(3):629-648, ix.
59. Perry C, Yu S, Chen J, Matharu KS, Stover PJ (2007) Effect of vitamin B6 availability on serine hydroxymethyltransferase in MCF-7 cells. Arch Biochem Biophys 462(1):21-27.